Your session is about to expire
← Back to Search
PET Radiotracer Imaging for Neuroendocrine Cancer
Study Summary
This trial is testing a new method to map and stage neuroendocrine tumors. If successful, this could help doctors treat these tumors more effectively in the future.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I am taking Xenazine for my condition.I am not taking cold medicines with phenylephrine, phenylpropanolamine, or pseudoephedrine.I can lie flat for an hour without discomfort.I am not taking any MAOI medications.You are pregnant or breastfeeding.You are afraid of being in small or enclosed spaces.I cannot lie flat for an hour.I am not on medications that affect PET scans for neuroendocrine tumors.I am not taking desipramine, amitriptyline, or imipramine.I do not use cocaine.I am not taking reserpine, labetalol, α-methyldopa, or clonidine for high blood pressure.I have been diagnosed with a neuroendocrine tumor.I am currently using nasal decongestants.
- Group 1: Planar scintigraphy/SPECT scans with radiotracer [123I]MIBG
- Group 2: PET/CT scan with radiotracer [18F]3F-PHPG
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
What medical purposes is the Positron emission tomography/computed tomography scan typically employed for?
"Positron emission tomography/computed tomography scan is a widely used treatment for paraganglioma, as well as neoplasm metastasis, primary neuroblastomas, and unresectable iobenguane-scan positive pheochromocytomas."
How many participants are being taken into this research initiative?
"Affirmative, the clinicaltrials.gov website indicates that this trial is actively enrolling participants. The initial post was published on October 19th 2020 and recently updated on November 8th 2022. This experiment requires 30 individuals from a single centre to complete it."
Are there any vacancies for individuals wishing to participate in this trial?
"The clinical trial is still open and accepting participants, as per the information found on clinicaltrials.gov. The trial was first posted in October 2020 with its most recent update taking place 11 months later."
Share this study with friends
Copy Link
Messenger